Selective estrogen receptor modulator medicinal chemistry at Merck. A review.
Selective estrogen receptor modulators (SERMs) have been the subject of extensive medicinal chemistry efforts at several pharmaceutical companies, including Merck. The Merck effort produced a wide variety of SERMs including ER-alpha selective antagonists and ER-beta agonists in addition to balanced (non-selective) analogs. This article will provide a broad overview of the Merck SERM medicinal chemistry effort as published in the literature through early 2008.
Merck Research Laboratories, RY800-B116 P.O. Box 2000, Rahway, NJ 07065, USA. tim_blizzard@merck.com
T A
TA
Blizzard
D000818:Animals; D002626:Chemistry, Pharmaceutical; D006801:Humans; D008024:Ligands; D020845:Selective Estrogen Receptor Modulators / Q000737:chemistry* / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D008024:Ligands; D020845:Selective Estrogen Receptor Modulators